1h Free Analyst Time
The latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Drugs In Development, 2022, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 12, 15, 2, 71, 34 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 2, 1, 13 and 3 molecules, respectively.
Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionReport CoverageDuchenne Muscular Dystrophy - OverviewDuchenne Muscular Dystrophy - Companies Involved in Therapeutics DevelopmentDuchenne Muscular Dystrophy - Drug ProfilesDuchenne Muscular Dystrophy - Dormant ProjectsDuchenne Muscular Dystrophy - Discontinued ProductsDuchenne Muscular Dystrophy - Product Development MilestonesAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
Duchenne Muscular Dystrophy - Therapeutics Development
Duchenne Muscular Dystrophy - Therapeutics Assessment
Featured News & Press Releases
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AAVogen Inc
- Alpha Anomeric
- American CryoStem Corp
- Anagenesis Biotechnologies SAS
- Antisense Therapeutics Ltd
- ARMGO Pharma Inc
- Astria Therapeutics Inc
- AUM LifeTech Inc
- Autotac Bio Inc
- Avidity Biosciences Inc
- Axolo Pharma Inc
- Bayer AG
- Biogen Inc
- BioIncept LLC
- Bioleaders Corp
- BioMarin Pharmaceutical Inc
- Biophytis SA
- CANbridge Life Sciences Ltd
- Capricor Therapeutics Inc
- Chengdu Fanxi Biopharma Co Ltd
- Code Biotherapeutics Inc
- Consortium.AI
- Constant Therapeutics LLC
- CRISPR Therapeutics AG
- Cumberland Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- DepYmed Inc
- DMD Therapeutics Inc
- DTx Pharma Inc
- Dyne Therapeutics Inc
- Dystrogen Therapeutics SA
- Edgewise Therapeutics Inc
- Editas Medicine Inc
- Eli Lilly and Co
- Eloxx Pharmaceuticals Inc
- Encell Co Ltd
- Entrada Therapeutics Inc
- Epirium Bio Inc
- EryDel SpA
- Evox Therapeutics Ltd
- FibroGen Inc
- FibroGenesis LLC
- Fulcrum Therapeutics Inc
- InnoBioscience LLC
- Italfarmaco SpA
- Ixchel Pharma LLC
- J2H Biotech
- Keros Therapeutics Inc
- KSbitugen Co Ltd
- LambdaGen Therapeutics
- Ludi Therapeutics
- Milo Biotechnology LLC
- Mitobridge Inc
- Mitochon Pharmaceuticals Inc
- MitoRx Therapeutics Ltd
- MyoGene Bio LLC
- Myos Inc
- Myosana Therapeutics Inc
- MyoTherix Inc
- Nippon Shinyaku Co Ltd
- NS Pharma Inc
- OliPass Corporation
- OMEICOS Therapeutics GmbH
- Oncocross Co Ltd
- Oncotelic Inc
- Pepgen Ltd
- PeptiDream Inc
- Pfizer Inc
- Pharmaxis Ltd
- PhaseBio Pharmaceuticals Inc
- Pliant Therapeutics Inc
- Progenitor Therapeutics Ltd
- Prothelia Inc
- PTC Therapeutics Inc
- PYC Therapeutics Ltd
- RASRx LLC
- RegenxBio Inc
- ReoStem LLC
- Ridgeline Therapeutics LLC
- Santhera Pharmaceuticals Holding AG
- Sarcomed AB
- Sarepta Therapeutics Inc
- Satellos Bioscience Inc
- Solid Biosciences Inc
- Stealth BioTherapeutics Corp
- SteroTherapeutics LLC
- Sutura Therapeutics Ltd
- Suzhou GenAssist Therapeutics Co Ltd
- Taiho Pharmaceutical Co Ltd
- Tivorsan Pharmaceuticals Inc
- Tolerion Inc
- Triplex Therapeutics Inc
- UGISense AG
- Ultragenyx Pharmaceutical Inc
- Vandria SA
- Vertex Pharmaceuticals Inc
- Vita Therapeutics Inc
- Wave Life Sciences Ltd
- Zata Pharmaceuticals Inc